UK‐PDRG (RR) 1998.

Methods	G: random number tables C: central allocation Patients/doctors/assessors all unblinded Intention‐to‐treat
Participants	UK 104 patients from arm 3 (bromocriptine) re‐randomised 51 to selegiline; 53 to control Incl and excl criteria as for UK‐PDRG 2001
Interventions	Treatment: selegiline 5 mg twice a day Control: no selegiline Both groups received levodopa
Outcomes	Deaths
Notes	Patients who initially could not tolerate bromocriptine were subsequently re‐randomised to selegiline or no selegiline Mean duration of FU: 6.8 years No washout
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "random number tables"
Allocation concealment (selection bias)	Low risk	Quote: "Randomization was carried out by an independent coordinator" Quote: "the investigators telephoned the coordinator for the treatment code, which was subsequently confirmed in writing."
Blinding (performance bias and detection bias) Doctors, All outcomes	High risk	Quote: “An open, randomised trial” Comment: Not blinded. Unlikely to bias mortality data but may influence other more subjective outcomes.
Blinding (performance bias and detection bias) Patients, All outcomes	High risk
Blinding (performance bias and detection bias) Outcome assessors, All outcomes	High risk
Incomplete outcome data (attrition bias) Mortality	Low risk	Rx: 51 re‐randomised, 51 analysed C: 53 re‐randomised, 53 analysed No reasons for loss documented.
Incomplete outcome data (attrition bias) Parkinsonian impairment & disability	Unclear risk	Outcome not assessed
Incomplete outcome data (attrition bias) Participants requiring levodopa	Unclear risk	Outcome not assessed
Incomplete outcome data (attrition bias) Motor fluctuations & dyskinesias	Unclear risk	Outcome not assessed
Selective reporting (reporting bias)	Unclear risk	No protocol available.
Other bias	Unclear risk	Quote: "sponsorship from Britannia Pharmaceuticals and Sandoz Products"